Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Conestat alfa is a recombinant analogue of the human C1 esterase inhibitor (C1-INH), produced using recombinant DNA technology in the milk of transgenic rabbits. It is a soluble, single-chain glycoprotein with an amino acid sequence identical to endogenous human C1-INH. Conestat alfa functions by inhibiting several proteases involved in the contact and complement systems, specifically activated C1s, kallikrein, factor XIIa, and factor XIa. This inhibition helps control excessive vascular permeability and inflammation associated with acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. The drug increases plasma levels of functional C1-INH activity and restores complement homeostasis in HAE patients[1][2][4][6]. Conestat alfa is approved for use in adults and adolescents aged 13 years or older for the treatment of acute HAE attacks[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on conestat alfa.